Max Bayer – Page 13 – Endpoints News

about the author

Max Bayer

Pharma Reporter

mbayer@endpointsnews.com

author articles

Six big R&D questions for Pfizer as science chief Dolsten exits

10 months ago

Acquired biotech accuses Novartis of letting IL-15 asset 'wither on the vine'

10 months ago

Lilly bests Novo Nordisk in observational study of GLP-1 drugs

10 months ago

Experts want to make it easier to get RSV vaccines. Did they make it harder instead?

11 months ago

Moderna wins $176M BARDA award to finance bird flu work

11 months ago

Cassava says two senior employees included in federal probes

11 months ago

Aerovate plans to lay off nearly all employees after trial failure

11 months ago

EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval

11 months ago

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

11 months ago

Lykos takes another hit as ICER lays out 'insufficient' evidence for MDMA-based treatment

11 months ago

Updated: CDC expands RSV vaccine recommendations, namely for adults 75 and older

11 months ago

Moderna's updated RSV vaccine disappoints with only 50% efficacy

11 months ago

Lilly becomes the latest pharma to tap OpenAI for help, this time for antibiotic work

11 months ago

Korea-based Bridge Biotherapeutics closes Boston office

11 months ago

UK taps Pfizer over hometown GSK to supply RSV vaccine doses

11 months ago

Lykos’ pain is others’ gain as psychedelic biotechs take notes from adcomm vote

11 months ago

FDA to pharma companies: Using CRO Synapse's studies 'unacceptable'

11 months ago

Corrected: Emergent sells Baltimore facility for $30M

11 months ago

Intra-Cellular reports a depression win, setting up future competition with AbbVie's Vraylar

11 months ago

GSK readies Blenrep's commercial re-launch in the US, and a push in second line

11 months ago

Aerovate’s stock craters after PAH drug fails Phase 2 study

11 months ago

Updated: Takeda’s Ovid-licensed drug fails two Phase 3 epilepsy studies

11 months ago

Gilead's M&A appetite is for deals in the 'mid-single-digit billions,' CEO says

11 months ago

States join Oklahoma effort to convince Supreme Court to let them regulate PBMs

11 months ago

First page Previous page 10 11 121314 Next page Last page